Aeterna Zentaris Announces First Patient Enrolled for Confirmatory Phase 3 Trial of Macrilen™ for the evaluation of AGHD

QUEBEC CITY , Nov. 19, 2015  Aeterna Zentaris Inc. (NASDAQ: AEZS)(AEZ.TO) (the "Company") announced today that the first patient has been enrolled for the Company's confirmatory Phase 3 clinical study to demonstrate the efficacy of Macrilen™ (macimorelin), a novel orally-active ghrelin agonist for use in evaluating adult growth hormone deficiency ("AGHD").

David A. Dodd , Chairman, President and Chief Executive Officer of the Company, remarked, "We remain committed to the development of Macrilen™ because of our confidence in its efficacy and safety, as well as the medical need for such a convenient test in the absence of an FDA-approved diagnostic test for AGHD." 

Published: 23 November 2015
Written by Editor
TSX   Up on News   Project Update  
Read more: Aeterna Zentaris Inc ( AWZ / AEZS )

The Traders Podcast with Rob Booker

Good morning Traders Podcast listeners! Welcome to Episode 491 where your host Rob Booker pulls aside the curtain for a moment and shares some insights from his private life about how to handle the emotions that come from difficulties. This type of character directly translates to trading. Enjoy and thanks for listening!

[ Listen to The Podcast ]

Published: 23 November 2015
Written by Editor

Anavex Announces Preparation of Regulatory Filings Based on Guidance From the FDA

NEW YORK, Nov. 18, 2015 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, announces that it is moving forward with the development program for ANAVEX 2-73.  Guidance received from the FDA confirms the Company’s strategy to advance ANAVEX 2-73 for the treatment of Alzheimer’s disease in a larger double-blinded, randomized, placebo-controlled Phase 2/3 trial.

“Working with a highly vulnerable patient population, the Company is proceeding in a rational, step-wise process.  Armed with the necessary data from the Phase 2a study to optimally design future trials, we look forward to expanding our development program,” said Kristina M. Capiak, Vice President Regulatory Affairs of Anavex.

Published: 18 November 2015
Written by Editor
Nasdaq   Up on News   biotech  
Read more: Anavex Life Sciences Corp ( AVXL )

Biocept Expands Patent Protection in Europe

European patent covers the use of antibodies in the capture and detection of rare cells from biological fluids used in the company's liquid biopsy, or blood-based, molecular diagnostic assays

SAN DIEGO, Nov. 11, 2015  -- Biocept, Inc. (BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the diagnosis and treatment of cancer, announces that the European Patent Office has awarded the patent, "DEVICES AND METHODS OF CELL CAPTURE AND ANALYSIS," as announced in the European Bulletin dated November 11, 2015. The patent covers the use of antibodies in the capture of rare cells, such as circulating tumor cells (CTCs), from blood as well as other biological fluids using the company's patented microchannel capture device. 

Published: 11 November 2015
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: Biocept Inc ( BIOC )

Skyworks to Acquire PMC-Sierra for $2 Billion in Cash

Creates an End-to-End Connectivity, Internet Infrastructure and Hyperscale Data Center Market Leader
Facilitates Client to Cloud Communications and Universal Access via Wireless or Wireline Networks
Immediately Accretive to Non-GAAP Earnings Upon Close
$75 Million of Annual Cost Synergies Targeted within 12 Months, Adding $0.75 of Earnings Power on an Annual Non-GAAP Basis
Skyworks Expects Q4 FY15 Results to be Better Than Guidance

WOBURN, Mass. & SUNNYVALE, Calif.- Skyworks Solutions, Inc. (SWKS), an innovator of high performance analog semiconductors connecting people, places and things, and PMC-Sierra, Inc. (PMC) (PMCS), a semiconductor and software solutions leader in storage, optical and mobile networks, today announced a definitive agreement under which Skyworks will acquire PMC for $10.50 per share in an all-cash transaction valued at approximately $2 billion. This acquisition solidifies Skyworks’ position as a highly diversified analog, RF and mixed signal semiconductor leader by significantly expanding its product portfolio, customer base and end market applications. Upon completion of the acquisition, Skyworks expects annual revenues of more than $4 billion with gross margin in the 55 percent range and operating margin exceeding 40 percent.

Published: 06 October 2015
Written by Editor
Nasdaq   M & A   Up on News  
Read more: PMC-Sierra Inc ( PMCS )
  1. Atmel Corporation ( ATML )
  2. Jabil Circuit Inc ( JBL )
  3. Metanor Resources Inc ( MTO )
  4. Aerie Pharmaceuticals Inc ( AERI )
  5. Nanosphere Inc ( NSPH )